CoChat
Sign Up
Cited by 32

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Matrix metalloproteinase inhibitor RO 28-2653 decreases liver metastasis by reduction of MMP-2 and MMP-9 concentration in BOP-induced ductal pancreatic cancer in Syrian Hamsters: Inhibition of matrix metalloproteinases in pancreatic cancer

Kilian, M., Gregor, J.I., Heukamp, I., Hanel, M., Ahlgrimm, M., Schimke, I., Kristiansen, G., Ommer, A., Walz, M.K., Jacobi, C.A., Wenger, F.A.·2006·Prostaglandins, Leukotrienes and Essential Fatty Acids
DOI 10.1016/j.plefa.2006.08.004
Open this paper in CoChat — free account

Abstract

Background Matrix metalloproteinases (MMP) are proteolytic enzymes which degrade the extracellular matrix and therefore play an important role in metastasis. However, the impact of MMP inhibitors (MMPI) on pancreatic cancer is still unclear. Thus we evaluated the influence of selective MMPI Ro 28-2653 on the incidence of liver metastases and the concentration of MMP-2 and MMP-9 in ductal pancreatic adenocarcinoma in Syrian hamster. Material and methods One hundred and thirty male Syrian hamsters were randomised into 8 groups (Gr.1-3: n=15, Gr.4-8: n=17). Pancreatic cancer was induced by weekly subcutaneous injection of 10mg N-nitrosobis-2-oxopropylamin (BOP)/kg body weight (Gr.4-8) while healthy control Gr. 1-3 received 0.5 ml sodium chloride 0.9%. Gr.1 and 4 had free access to a standard diet, Gr. 2, 3 and 5-8 received a diet rich in polyunsaturated fatty acids, which increases liver metastasis in this model. In week 17 oral therapy started: Gr.3 and 6: 60 mg Eudragit/kg body weight/d (vehicle of MMPI), Gr.7 and 8: 40 mg, respectively, 120 mg RO 28-2653/kg body weight/d; Gr.1, 2, 4, 5: no therapy. After 30 weeks all hamsters were sacrificed and histopathologically examined. Additionally concentrations of MMP-2 and MMP-9 were measured in non-metastatic liver and liver metastases. Results Concentrations of MMP-2 and MMP-9 in liver metastases were decreased by high- and low-dose therapy with MMPI. Furthermore, the incidence of liver metastases was significantly reduced by low-d…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.plefa.2006.08.004

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Ro 28-2653 is an orally available, brain-penetrant inhibitor with high specificity for MT1-MMP, MMP2, and MMP9.

    “Ro 28-2653 is an orally available, brain-penetrant inhibitor with high specificity for MT1-MMP, MMP2, and MMP9.”

    From MT1-MMP inhibition rejuvenates ageing brain and rescues cognitive deficits in obesity (2025) · cites this paper as [33]

  • As a hydroxamic acid-based MMP inhibitor, Ro 28-2653 may also display lower binding affinity for other MMPs, as well as for ADAM and ADAMTS metalloproteinases.

    “As a hydroxamic acid-based MMP inhibitor, it may also display lower binding affinity for other MMPs, as well as for ADAM and A Disintegrin and Metalloproteinase with Thrombospondin Motifs (ADAMTS) metalloproteinases31–35.”

    From MT1-MMP inhibition rejuvenates ageing brain and rescues cognitive deficits in obesity (2025) · cites this paper as [33]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 33

  1. Hawes, 2000, A multispeciality approach to the diagnosis and management of pancreatic cancer, Am. J. Gastroenterol., 95, 17, 10.1111/j.1572-0241.2000.01699.x · DOI
  2. Warshaw, 1992, Pancreatic carcinoma, N. Engl. J. Med., 326, 455, 10.1056/NEJM199202133260706 · DOI
  3. Zalatnai, 2003, Pancreatic Cancer—a Continuing Challenge in Oncology, Pathol. Oncol. Res., 9, 252, 10.1007/BF02893388 · DOI
  4. Alexakis, 2004, Current standards of surgery for pancreatic cancer, Br. J. Surg., 91, 1410, 10.1002/bjs.4794 · DOI
  5. Amikura, 1995, The time of occurrence of liver metastasis in carcinoma of the pancreas, Int. J. Pancreatol., 17, 139, 10.1007/BF02788531 · DOI
  6. Shore, 2003, Review article: chemotherapy for pancreatic cancer, Aliment Pharmacol. Ther., 18, 1049, 10.1111/j.1365-2036.2003.01781.x · DOI
  7. Neoptolemos, 2003, Adjuvant therapy in pancreatic cancer: historical and current perspectives, Ann. Oncol., 14, 675, 10.1093/annonc/mdg207 · DOI
  8. Gross, 1962, Collagenolytic activity in amphibian tissues: a tissue culture assay, Proc. Natl. Acad. Sci., 48, 1014, 10.1073/pnas.48.6.1014 · DOI
  9. Maquoi, 2004, Anti-invasive, anti-tumoral, and anti-angiogenic efficacy of a Pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinase inhibitor, Clin. Cancer Res., 10, 4038, 10.1158/1078-0432.CCR-04-0125 · DOI
  10. Qian, 2001, Expression of Thrombospondin-1 in human pancreatic adenocarcinomas: role in matrix metalloproteinase-9 production, Pathol. Oncol. Res., 7, 251, 10.1007/BF03032381 · DOI
  11. Zervos, 1999, Matrix metalloproteinase (MMP) inhibition selectively decreases type II MMP activity in a murine model of pancreatic cancer, J. Surg. Res., 81, 65, 10.1006/jsre.1998.5447 · DOI
  12. Koshiba, 1998, Involvement of matrix metalloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma, Am. cancer soc., 642-650
  13. Zervos, 1999, Matrix metalloproteinase inhibition suppresses MMP-2 activity and activation of Panc-1 cells in vitro, J. Surg. Res., 84, 162, 10.1006/jsre.1999.5632 · DOI
  14. Coussens, 2002, Matrix metalloproteinase inhibitors and cancer: trials and tribulations, Science, 295, 2387, 10.1126/science.1067100 · DOI · Paper page
  15. Yip, 1999, Matrix metalloproteinase inhibitors: applications in oncology, 17, 387
  16. Wojtowicz-Praga, 1997, Matrix metalloproteinase inhibitors, Invest. New Drugs, 15, 61, 10.1023/A:1005722729132 · DOI
  17. Wenger, 2000, The impact of laparoscopic biopsy of pancreatic lymph nodes with helium and carbon dioxide on port site and liver metastasis in BOP-induced pancreatic cancer in hamster, Clin. Exp. Metastasis, 18, 11, 10.1023/A:1026515917720 · DOI
  18. Wenger, 1999, Does dietary alpha-linoleic acid promote liver metastasis pancreatic carcinoma initiated by BOP in Syrian hamsters?, Ann. Nutr. Metabol., 43, 121, 10.1159/000012776 · DOI
  19. Herrington, 1993, Effects of high fat diet and cholecystokinin receptor blockade on pancreatic growth and tumour initiation in the hamster, Carcinogenesis, 14, 1021, 10.1093/carcin/14.5.1021 · DOI
  20. Birt, 1989, Enhancement of pancreatic carcinogenesis in hamsters fed a high fat diet ad libitum and at controlled calorie intake, Cancer Res., 49, 5848
  21. UKCCCR-Guidelines for the welfare of animals in experimental neoplasia. Cancer Metastasis Rev. 8: (1989); 82–88. · DOI
  22. Meijers, 1990, Role of cholecystokinin in the development of BOP-induced pancreatic lesions in hamsters?, Carcinogenesis, 11, 2223, 10.1093/carcin/11.12.2223 · DOI
  23. Bloomstom, 2002, MMP-2 and TIMP-1 are derived from, not in response to, pancreatic cancer, J. Surg. Res., 102, 35, 10.1006/jsre.2001.6317 · DOI
  24. Longnecker, 1991, Experimental cancer of the pancreas, Curr. Opin. Gastroeterol, 7, 731, 10.1097/00001574-199110000-00008 · DOI
  25. Pour, 1981, Current knowledge of pancreatic carcinogenesis in the hamster and its relevance to the human disease, Cancer, 47, 1573, 10.1002/1097-0142(19810315)47:6+<1573::AID-CNCR2820471420>3.0.CO;2-K · DOI
  26. Zervos, 1997, Matrix metalloproteinase inhibition attenuates human pancreatic cancer growth in vitro and decreases mortality and tumorgenesis in vivo, J. Surg. Res., 69, 367, 10.1006/jsre.1997.5086 · DOI
  27. Matsushita, 2001, Antitumor effect of a new selective matrix metalloproteinase inhibitor, MMI-166, on experimental pancreatic cancer, Int. J. Cancer, 92, 434, 10.1002/ijc.1199 · DOI
  28. Jimenenz, 2000, Effect of matrix metalloproteinase inhibition on pancreatic cancer invasion and metastasis, Ann. Surg., 231, 644, 10.1097/00000658-200005000-00004 · DOI
  29. Deruygina, 1998, Remodelling of collagen matrix by human tumor cells requires activation and cell surface association of matrix metalloproteinase-2, Cancer Res., 58, 3743
  30. Bramhall, 2002, Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial, Br. J. Cancer, 86, 1864, 10.1038/sj.bjc.6600310 · DOI
  31. Zucker, 2000, Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment, Oncogene, 19, 6642, 10.1038/sj.onc.1204097 · DOI
  32. Coussens, 2002, Matrix metalloproteinase inhibitors and cancer: trials and tribulations, Science (Wash DC), 295, 2387, 10.1126/science.1067100 · DOI · Paper page
  33. Fingleton, 2003, Matrix metalloproteinase inhibitors for cancer therapy: the current situation and future prospects, Expert Opin. Ther. Targets, 7, 385, 10.1517/14728222.7.3.385 · DOI

Cited by

Sorted by citations

Metadata

Authors
Kilian, M., Gregor, J. I., Heukamp, I., Hanel, M., Ahlgrimm, M., Schimke, I., Kristiansen, G., Ommer, A., Walz, M. K., Jacobi, C. A., & Wenger, F. A.
Venue
Prostaglandins, Leukotrienes and Essential Fatty Acids
Publisher
Elsevier BV
Published
2006-12
Volume
75
Issue
6
Pages
429-434
ISSN
0952-3278
DOI
10.1016/j.plefa.2006.08.004
Cited by
32
References
1
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review